What REDEFINE 1 tested
This 68-week randomized trial enrolled 3,417 adults without diabetes who had obesity or overweight with a weight-related complication. It assigned 2,108 to CagriSema, 302 to semaglutide alone, 302 to cagrilintide alone and 705 to placebo. The weekly target was 2.4 mg for each active component, and the protocol allowed dose adjustments. The CagriSema trials in type 2 diabetes answer a separate question in people with diabetes. In REDEFINE 1, every group received a lifestyle intervention [1].
How much did cagrilintide add?
The primary analysis estimated outcomes regardless of whether participants stayed on assigned treatment. At week 68, the combination produced an estimated 5.5 percentage points more weight loss than semaglutide alone (95% CI 4.3–6.7), 8.9 more than cagrilintide alone (7.7–10.1) and 17.3 more than placebo (16.6–18.1) [1]. The GLP-1 weight-loss evidence guide explains how the study population and follow-up period affect the interpretation of these averages.
Gastrointestinal adverse events occurred in 79.6% of the combination group, 73.8% of the semaglutide group, 54.0% of the cagrilintide group and 39.9% of the placebo group. The events were mainly temporary and mild to moderate, and included nausea, vomiting, diarrhea, constipation and abdominal pain[1].
U.S. regulatory status
Novo Nordisk submitted CagriSema for FDA review for weight management in December 2025. As of November 14, 2026, the combination remains investigational[2]. The FDA says cagrilintide cannot be used in compounding[3]. Research on compounded semaglutide injections concerns separate formulations and cannot establish the effects of the fixed-dose combination studied in REDEFINE 1.